Sign up Australia
Proactive Investors - Run By Investors For Investors

ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal

The deal allows IPA to become a single source provider of services across the full antibody discovery value chain, the firm told investors.
ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal
IPA develops antibodies to support research and development programs

ImmunoPrecise Antibodies Ltd (CVE:IPA, OTC PINK:IPATF) is set to buy ModiQuest Research BV in a C$10.57mln deal, which bolsters its global acquisition strategy and will add to both revenue and earnings, it said.

It allows IPA to become a single source provider of services across the full antibody discovery value chain, it told investors.

In simple terms, IPA develops antibodies to support research and development programs at pharmaceutical and biotechnology companies, as well as academic research labs.

Targetting antigens..

Antibodies  can target molecules, or antigens. They are produced by the immune  system to help stop intruders from harming the body.

This acquisition will enhance the firm's capacity for generating human antibodies, it said.

Privately-held ModiQuest, based in the Netherlands, can generate very large panels of monoclonal antibodies from various backgrounds including mouse, rat, rabbit, chicken, llama and human

ModiQuest serves clients in Europe, the US, Asia and Russia and during 2016, it posted revenues of €2,009,374 (CAD $3,037,249) and earnings of €671,799 (CAD $1,015,451).

"In acquiring ModiQuest Research B.V, IPA becomes a leading integrated antibody solutions company with global reach," said Dr James Kuo,  chairman and interim president of the company.

A binding letter of intent..

Under a binding letter of intent, the  parties have agreed to negotiate a definitive agreement, whereby IPA will acquire all ModiQuest shares for C$10.57mln, of which C$3.775mln will be paid in cash on closing.

Also, C$3.775mln  will be satisfied by issuing around 6.6mln shares on closing, and C$2mln in deferred payments over three years.

The deferred payments will be made in three equal installments of cash and equity totaling (C$$1,006,665) on each anniversary date following closing of the transaction.

The parties will be entitled to carry out due diligence of each other until February 15 next year, and if satisfied, will  enter a definitive agreement by February 28.

Shares added over 5% to C$0.60 each..

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use